Swiss-listed investment company BB Biotech (SWX:BION) says it is looking back on a tough year for the biotechnology sector even as it reported a total share return of 8.3% in Swiss francs (13.3% in Euro). Some of this was attributed to the performance of the USD, but the biotech fund saw its net asset value off by over 14% for the year.
The board of directors has, however, said it will be proposing a regular dividend of CHF 3.85 per share at its AGM in March. This would be consistent with a dividend policy introduced in 2013, and will equate to a 5% yield.
Want the full story? Access all of The Armchair Trader's content for just £5.99 per month.
Get weekly investment ideas and tips that will take your investing to the next level. Sign up here.
Free 28 day trial. Cancel anytime.
Log In or Sign Up to Armchair Trader+Already a member? Log in here:
Not a member? Sign up now or see the membership benefits
Further content of this article is not available as it is for members only. Please visit the registration page for Armchair Trader Plus+ for further details on the benefits of becoming a member.
